COVID-19 VACCINE TRIALS
Zydus said it has received approval from Indian authorities to start human trials for its COVID-19 vaccine contender
ZyCov -D showed a ‘strong immune response’ in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus said
Zydus Cadila, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider
Zydus earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions
Cadila was founded in 1952 by Ramanbhai Patel
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group
In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative
In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price
In 2015 the company acquired another Indian pharmaceutical company called German Remedies
In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth
Good health, happiness, joy, growth, togetherness, discovery, learning, exploration, evolution, transformation, aspirations, are all intrinsically linked with life. Zydus is dedicated to all these dimensions
The group has forged meaningful partnerships with its key stakeholders both internal and external, partners in progress and the community at large
The group’s philosophy for community engagement is based on the principle of volunteerism and is an intensive, comprehensive and sustainable programme.
No comments:
Post a Comment